Skip to main content
SpringerLink
Log in

Reviewing CEAs of treatments for advanced NSCLC

  • Review
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. epidermal growth factor receptor

  2. anaplastic lymphoma kinase

Reference

  • Gallacher D, et al. A Systematic Review of Economic Evaluations Assessing the Cost-Effectiveness of Licensed Drugs Used for Previously Treated Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Negative Advanced/Metastatic Non-Small Cell Lung Cancer. Clinical Drug Investigation : 3 Oct 2019

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reviewing CEAs of treatments for advanced NSCLC. PharmacoEcon Outcomes News 839, 32 (2019). https://doi.org/10.1007/s40274-019-6313-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6313-8

Search

Navigation